Zydelig Alternatives Compared
Zydelig (idelalisib) | Treanda (bendamustine) | Rituxan (rituximab) |
|
---|
Zydelig (idelalisib) | Treanda (bendamustine) | Rituxan (rituximab) |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Zydelig is an oral PI3K inhibitor that may be used in combination with rituximab for the treatment of relapsed chronic lymphocytic leukemia. Severe and potentially life-threatening reactions have... View more |
Prescription only
Treanda is a cytotoxic agent that must be administered by a health professional and may be used to treat chronic lymphocytic leukemia (CLL) and a certain type of non-Hodgkin lymphoma. It can cause... View more |
Prescription only
Rituxan is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate and may be used to treat Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid... View more |
Related suggestions Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
|
|||||||
More about Zydelig (idelalisib) | More about Treanda (bendamustine) | More about Rituxan (rituximab) | ||||||||
Ratings & Reviews | ||||||||||
Zydelig has an average rating of 4.5 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 50% reported a negative effect. |
Treanda has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Rituxan has an average rating of 8.2 out of 10 from a total of 50 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 10% reported a negative effect. |
||||||||
Drug Class | ||||||||||
Side Effects | ||||||||||
Generic Availability | ||||||||||
N/A |
||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Rituxan prices |
||||||||
Dosage Forms Available | ||||||||||
|
|
|
||||||||
Brand Names | ||||||||||
N/A |
Other bendamustine brands include: Belrapzo, Bendeka, Vivimusta | Other rituximab brands include: Riabni, Ruxience, Truxima | ||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
8.2 hours |
N/A |
59.8 hours |
||||||||
CSA Schedule ** View glossary of terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 874 drugs are known to interact with Zydelig:
|
A total of 280 drugs are known to interact with Treanda:
|
A total of 176 drugs are known to interact with Rituxan:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | ||||||||||
First Approval Date | ||||||||||
July 23, 2014 |
October 31, 2008 |
N/A |
||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.